/EINPresswire.com/ -- TORONTO, ON--(Marketwired - August 09, 2017) - During a live broadcast on Tuesday, August 29, 2017 at 11am EDT (4pm BST/UK), industry experts from INC Research/inVentiv Health will discuss the factors that sponsors must take into account when designing and executing immunotherapy clinical trials, beginning with a review of the current landscape.

Unique issues arise with each novel immunotherapy treatment, including the selection of relevant endpoints, inclusion of appropriate patients, and surveillance of immuno-modulated adverse reactions. These new immunotherapies pose further challenges for sponsors in ensuring regulatory approvability and compliance, given that there is a separate and very different regulatory framework for each novel mechanism of action. In both the US and EU, distinct regulations apply to cell-based medicinal products, gene therapy, antibodies, and therapeutic vaccines.

Once scientific and regulatory plans have been determined, planning how many sites or how much time it will take to enroll the required number of patients into a trial of a new immunotherapy is sometimes more art than science because there is comparatively little established past history on which to base patient enrollment projections. Therefore, the feasibility processes of estimating the enrollment rate for newer immunotherapies necessarily involves supplementing evidence with the judgment of a multidisciplinary team of experts.

Clinical trials of cancer immunotherapies are, as a result, quite different from those with other cancer therapeutics; they require special planning and are subject to unique medical, regulatory, and operational considerations.

Learning Objectives:

• Review classes of immunotherapies and their associated mechanisms of action
• Understand challenges in protocol design and safety surveillance of new trials of immunotherapies
• Identify potential regulatory approval challenges and regulations applicable to novel immunotherapies
• Understand methods for estimating feasibility and planning on trials of immunotherapy products

For more information or to register for this complimentary session, visit: Planning and Conducting Trials of the Latest Immunotherapies

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit: http://xtalks.com

For information about hosting a webinar visit: http://xtalks.com/sponsorship.ashx

Image Available: http://www.marketwire.com/library/MwGo/2017/8/9/11G143977/Images/INC-and-iVH_Lockup-6d60963e59d3a1679f933c889dbac303.jpg